Dermatology
News
Bertilimumab granted orphan drug status for bullous pemphigoid
A pivotal phase 2/3 trial of bertilimumab will begin next year, according to the company.
From the Journals
Alopecia areata linked to mental health disorders
Inpatients with alopecia areata are at higher risk for numerous psychiatric disorders, including anxiety disorders, ADHD, dementia, and mood and...
From the Journals
Psoriasis registry study provides more data on infliximab’s infection risk
Infliximab was associated with a statistically significant increased risk of serious infection, compared with non-biologic systemic treatments.
Conference Coverage
Climbing the therapeutic ladder in eczema-related itch
WASHINGTON – Oral medications include antihistamines, followed by “more intense”...
Video
CUBE-C initiative aims to educate about atopic dermatitis
WASHINGTON – “The hope is that programs like these pop up all over the place.”
Latest News
Oral drug seen preventing angioedema attacks
A novel agent led to a nearly 75% reduction in monthly attacks among people with a rare genetic disorder.
Latest News
Early-onset atopic dermatitis linked to elevated risk for seasonal allergies and asthma
LAKE TAHOE, CALIF. – The relative risk for prevalent seasonal allergies was about 18% lower in the late-onset group, compared with those in the...
From the Journals
Patient survey results highlight disease burden in atopic dermatitis
The results “support the importance of incorporating the patient perspective into assessment of AD,” the authors wrote.
News
FDA approves topical anticholinergic for primary axillary hyperhidrosis
Glycopyrronium, approved for children and adults ages 9 years and older, comes in a single-use cloth wipe applied once a day to both axillae.
From the Journals
Elderly patients with psoriasis can benefit from biologics with low rates of adverse events
Age should not be the deciding factor in which psoriasis patients receive treatment with these powerful therapies, according to Italian...
Conference Coverage
Adalimumab strikes out for aortic inflammation in psoriasis
ORLANDO – Ustekinumab shows promise, but “we are still not certain.”